Nishtha Attri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nishtha Attri has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Arindam Pramanik
Amity Institute of Biotechnology, Amity University, Sector 125, Noida, 201301, Delhi, India
1 shared publication - Jhimli Banerjee
Department of Physiology, University of Gour Banga, Malda, India
1 shared publication - Sandeep Kumar Dash
Department of Physiology, University of Gour Banga, Malda, India
1 shared publication - Shazana Hilda Shamsuddin
Pathology Department School of Medical Sciences, Universiti Sains Malaysia Kota Bharu Kelantan Malaysia
1 shared publication - Swarnali Das
Department of Physiology, University of Gour Banga, Malda, India
1 shared publication
Latest Publications
- Open Access
- 30 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Liposomes to cubosomes: The evolution of lipidic nanocarriers and their cutting-edge biomedical applications
Lipidic nanoparticles have undergone extensive research towards the exploration of their diversely ranging therapeutic applications. Although several liposomal formulations are in the clinics (e.g., DOXIL) for cancer therapy there are many challenges associated with the traditional liposomes. To address these issues, modifications in liposomal structure and further functionalization are desirable, leading to the emergence of solid lipid nanoparticles and the more recent liquid lipid nanoparticles. In this context, ‘cubosomes’, third-generation lipidic nanocarriers, have attracted significant attention due to their numerous advantages, including their porous structure, structural adaptability, high encapsulation efficiency resulting from their extensive internal surface area, enhanced stability, and biocompatibility. Cubosomes offer the potential for both enhanced cellular uptake and controlled release of encapsulated payloads. Beyond cancer therapy, cubosomes have demonstrated effectiveness in wound healing, antibacterial treatments, and various dermatological applications. In the article, the authors provide an overview of the evolution of lipidic nanocarriers, spanning from conventional liposomes to solid lipid nanoparticles, with a special emphasis on the development and applications of cubosomes. Additionally, it delves into recent applications and pre-clinical trials associated with cubosome formulations, which could be of significant interest to readers from backgrounds in nanomedicine and clinicians.
- 30 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessLiposomes to cubosomes: The evolution of lipidic nanocarriers and their cutting-edge biomedical applications
Lipidic nanoparticles have undergone extensive research towards the exploration of their diversely ranging therapeutic applications. Although several liposomal formulations are in the clinics (e.g., DOXIL) for cancer therapy there are many challenges associated with the traditional liposomes. To address these issues, modifications in liposomal structure and further functionalization are desirable, leading to the emergence of solid lipid nanoparticles and the more recent liquid lipid nanoparticles. In this context, ‘cubosomes’, third-generation lipidic nanocarriers, have attracted significant attention due to their numerous advantages, including their porous structure, structural adaptability, high encapsulation efficiency resulting from their extensive internal surface area, enhanced stability, and biocompatibility. Cubosomes offer the potential for both enhanced cellular uptake and controlled release of encapsulated payloads. Beyond cancer therapy, cubosomes have demonstrated effectiveness in wound healing, antibacterial treatments, and various dermatological applications. In the article, the authors provide an overview of the evolution of lipidic nanocarriers, spanning from conventional liposomes to solid lipid nanoparticles, with a special emphasis on the development and applications of cubosomes. Additionally, it delves into recent applications and pre-clinical trials associated with cubosome formulations, which could be of significant interest to readers from backgrounds in nanomedicine and clinicians.